CN101903385B - 作为组胺h4受体拮抗剂的4-氨基嘧啶衍生物 - Google Patents

作为组胺h4受体拮抗剂的4-氨基嘧啶衍生物 Download PDF

Info

Publication number
CN101903385B
CN101903385B CN200880121970XA CN200880121970A CN101903385B CN 101903385 B CN101903385 B CN 101903385B CN 200880121970X A CN200880121970X A CN 200880121970XA CN 200880121970 A CN200880121970 A CN 200880121970A CN 101903385 B CN101903385 B CN 101903385B
Authority
CN
China
Prior art keywords
alkyl
formula
compound according
compound
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880121970XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101903385A (zh
Inventor
E·卡塞列尔冈萨雷斯
E·M·梅迪纳福恩特斯
R·索利瓦索利瓦
M·维尔基里博纳多
J·马蒂维亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palau Pharmaceutical Sole Proprietorship Co
Original Assignee
Palau Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palau Pharma SA filed Critical Palau Pharma SA
Publication of CN101903385A publication Critical patent/CN101903385A/zh
Application granted granted Critical
Publication of CN101903385B publication Critical patent/CN101903385B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200880121970XA 2007-12-21 2008-12-18 作为组胺h4受体拮抗剂的4-氨基嘧啶衍生物 Active CN101903385B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07382006 2007-12-21
EP07382006.0 2007-12-21
US3153408P 2008-02-26 2008-02-26
US61/031,534 2008-02-26
PCT/EP2008/067950 WO2009080721A2 (en) 2007-12-21 2008-12-18 4 -aminopyrimidine derivatives as histamine h4 receptor antagonists

Publications (2)

Publication Number Publication Date
CN101903385A CN101903385A (zh) 2010-12-01
CN101903385B true CN101903385B (zh) 2013-11-06

Family

ID=39473347

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880121970XA Active CN101903385B (zh) 2007-12-21 2008-12-18 作为组胺h4受体拮抗剂的4-氨基嘧啶衍生物

Country Status (24)

Country Link
US (1) US8431580B2 (enExample)
EP (1) EP2235012B1 (enExample)
JP (1) JP5498396B2 (enExample)
KR (1) KR101639819B1 (enExample)
CN (1) CN101903385B (enExample)
AR (1) AR069814A1 (enExample)
AU (1) AU2008341678B2 (enExample)
BR (1) BRPI0820779B8 (enExample)
CA (1) CA2709650C (enExample)
CL (1) CL2008003811A1 (enExample)
CY (1) CY1114427T1 (enExample)
DK (1) DK2235012T3 (enExample)
ES (1) ES2430210T3 (enExample)
HR (1) HRP20130918T1 (enExample)
IL (1) IL206413A (enExample)
PE (1) PE20091330A1 (enExample)
PL (1) PL2235012T3 (enExample)
PT (1) PT2235012E (enExample)
RU (1) RU2489430C2 (enExample)
SI (1) SI2235012T1 (enExample)
TW (1) TWI429440B (enExample)
UA (1) UA101963C2 (enExample)
WO (1) WO2009080721A2 (enExample)
ZA (1) ZA201005179B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
MX2011006682A (es) 2008-12-22 2011-07-13 Merck Patent Gmbh Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirim idin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion.
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
SI2493895T1 (sl) 2009-10-29 2017-10-30 Vectura Limited Derivati heteroarila, ki vsebujejo N, kot inhibitorji JAK3 kinaze
MX345142B (es) * 2009-12-23 2017-01-18 Palau Pharma Sa Derivados de aminoalquilpirimidina como antagonistas del receptor h4 de histamina.
PL2858647T3 (pl) 2012-06-08 2018-10-31 Sensorion Inhibitory receptora h4 do leczenia szumów usznych
ES2946551T3 (es) 2017-10-17 2023-07-20 Palau Pharma S L U Síntesis de compuestos de 4-aminopirimidina
GB201817047D0 (en) 2018-10-19 2018-12-05 Heptares Therapeutics Ltd H4 antagonist compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1505064A1 (en) * 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
WO2005054239A1 (en) * 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2361869C2 (ru) * 2002-02-05 2009-07-20 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Новые арил- и гетероарилпиперазины
EA010568B1 (ru) * 2003-12-15 2008-10-30 Ньюрокрайн Байосайнсиз Инк. 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
ATE502936T1 (de) * 2005-04-11 2011-04-15 Almirall Sa 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten
BRPI0615880A2 (pt) * 2005-09-13 2011-05-31 Palau Pharma Sa compostos derivados de 2-aminopirimidina como moduladores da atividade de receptor da histamina h4, uso dos mesmos e composição farmacêutica
WO2007084914A2 (en) * 2006-01-17 2007-07-26 Neurocrine Biosciences, Inc. Phenoxy-substituted pyrimidines as adenosine receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1505064A1 (en) * 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
WO2005054239A1 (en) * 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mai Zhang et al..The histamine H-4 receptor in autoimmune disease.《EXPERT OPINION ON INVESTIGATIONAL DRUGS》.2006,第15卷(第11期),1443-1452. *

Also Published As

Publication number Publication date
JP5498396B2 (ja) 2014-05-21
AR069814A1 (es) 2010-02-17
KR20100096184A (ko) 2010-09-01
HRP20130918T1 (hr) 2013-11-08
HK1149003A1 (en) 2011-09-23
CY1114427T1 (el) 2016-08-31
RU2010130418A (ru) 2012-01-27
UA101963C2 (en) 2013-05-27
RU2489430C2 (ru) 2013-08-10
IL206413A0 (en) 2010-12-30
PT2235012E (pt) 2013-08-28
WO2009080721A3 (en) 2009-09-11
AU2008341678B2 (en) 2013-03-21
US20110039817A1 (en) 2011-02-17
WO2009080721A2 (en) 2009-07-02
BRPI0820779A2 (pt) 2015-06-16
TW200938197A (en) 2009-09-16
EP2235012A2 (en) 2010-10-06
BRPI0820779B1 (pt) 2020-02-04
CA2709650C (en) 2016-06-07
KR101639819B1 (ko) 2016-07-14
US8431580B2 (en) 2013-04-30
AU2008341678A1 (en) 2009-07-02
IL206413A (en) 2015-06-30
PE20091330A1 (es) 2009-09-07
CA2709650A1 (en) 2009-07-02
ZA201005179B (en) 2012-03-28
SI2235012T1 (sl) 2013-11-29
CN101903385A (zh) 2010-12-01
JP2011506566A (ja) 2011-03-03
EP2235012B1 (en) 2013-07-17
CL2008003811A1 (es) 2009-05-22
PL2235012T3 (pl) 2013-12-31
BRPI0820779B8 (pt) 2021-05-25
DK2235012T3 (da) 2013-10-07
TWI429440B (zh) 2014-03-11
ES2430210T3 (es) 2013-11-19

Similar Documents

Publication Publication Date Title
TWI429440B (zh) ４－胺基－嘧啶衍生物類
WO2009068512A1 (en) 2 -amino-pyrimidine derivatives as histamine h4 antagonists
WO2009077608A1 (en) 2 -aminopyrimidine derivatives as histamine h4 antagonists
CN109761960A (zh) 抗耐药抗肿瘤egfr抑制剂的制备方法
CN102803248B (zh) 作为组胺h4受体拮抗剂的氨烷基嘧啶
WO2009115496A1 (en) Furo [3, 2-d] pyrimidine derivatives as h4 receptor antagonists
WO2009056551A1 (en) Furo[3,2-d]pyrimidine derivatives
CN117157284A (zh) Ctla-4小分子降解剂及其应用
HK1149003B (en) 4-aminopyrimidine derivatives as histamine h4 receptor antagonists
WO2010094721A1 (en) Piperidin-pyrimidine derivatives as antagonists of histamine h4 receptor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20241111

Address after: Barcelona, Spain

Patentee after: Palau Pharmaceutical Sole Proprietorship Co.

Country or region after: Spain

Address before: Barcelona, Spain

Patentee before: PALAU PHARMA, S.A.

Country or region before: Spain

TR01 Transfer of patent right